TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03834506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral tablets
Study: NCT03698383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilars(Herzuma), Gedatolisib
Description: * Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg
Study: NCT04827849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured education and follow-up
Description: The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period.
Study: NCT03834506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study: NCT05423938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetic
Description: It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
Study: NCT00445848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study: NCT00659217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Autologous MSC transplantation
Study: NCT01442506

Intervention type: OTHER
Intervention: biopsies
Description: taking biopsies

Intervention type: OTHER
Intervention: biopsy
Description: biopsy
Study: NCT06761573

Intervention type: DEVICE
Intervention: Bilateral Bispetral Index Monitor will be applied on forehead of our patients, before surgery begins
Description: In patients undergoing surgery and general anesthesia, the investigators want to examine -using bilateral BIS monitor- synthetic electroencephalographic differences between the two cerebral hemispheres (ASYM) to evaluate any correlation with the development of POD and POCD in the post-operative period.
Study: NCT06761430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearPlasma
Description: ClearPlasmais an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasmaTM is a non-pyrogenic, sterile, single-use medical device.
Study: NCT01817673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 20 g/d for 5 d followed by 5 g/d throughout the trial

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02736266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
Study: NCT02187523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ FDC
Study: NCT02098369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written education material (basic)
Description: Education material on COPD distributed to all participants.
Study: NCT01385800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: Intradermal injection 1 x 8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: Intradermal injection 1 x 8 administrations 2 weeks apart
Study: NCT02098369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written education material (basic)
Description: Education material on COPD distributed to all participants.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written education material (basic)
Description: Education material on COPD distributed to all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional education material
Description: Additional education material sent to participants in the proactive and reactive arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional education material
Description: Additional education material sent to participants in the proactive and reactive arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PELICAN-Proactive
Description: In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PELICAN-Reactive
Description: Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
Study: NCT03975127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text
Description: A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
Study: NCT01991223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex infusion
Description: Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS infusion
Description: Normal saline will be infused during surgery
Study: NCT01633515

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intralesional cryotherapy
Description: The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received).
Study: NCT04951271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution focused approach
Description: The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
Study: NCT02378194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks, once daily oral administration
Study: NCT03725696

Intervention type: DIAGNOSTIC_TEST
Intervention: Semen Analysis
Description: Sperm counts will be determined by semen analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal panel
Description: Blood test for LH, FSH, testosterone, and estradiol

Intervention type: PROCEDURE
Intervention: RYGB Gastric Bypass
Description: Roux-en-Y Gastric Bypass

Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF Survey
Description: International Index of Erectile Function is a validated 5-question survey examining sexual health in men
Study: NCT01963403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE 30mcg/LNG 150mcg
Description: 1 pill per day; daily during study participation (up to 84 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day; daily during study participation (up to 84 days)
Study: NCT04087694

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdecompression
Description: comparative surgical treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdecompression
Description: comparative surgical treatment
Study: NCT03472404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Brace augmented ankle Ligament reconstruction
Description: internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brostrom-Gould ankle Ligament reconstruction
Description: Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
Study: NCT00589914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RISPERDAL CONSTA
Description: RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
Study: NCT01385800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: Intradermal injection 1 x 8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 8 administrations 2 weeks apart
Study: NCT00589914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
Study: NCT03032757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: 240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: 240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: 240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: 240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
Study: NCT01854866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-packaging microparticles
Description: Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
Study: NCT02590198

Intervention type: OTHER
Intervention: ANAES algorithm
Description: care as recommended by ANAES, with ANAES algorithm

Intervention type: OTHER
Intervention: ANAES algorithm
Description: care as recommended by ANAES, with ANAES algorithm

Intervention type: OTHER
Intervention: PCT algorithm
Description: care based on PCT algorithm

Intervention type: OTHER
Intervention: PCT algorithm
Description: care based on PCT algorithm
Study: NCT03653897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Capsule- Active
Description: A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
Study: NCT02378194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-003 (800mg/day)
Description: 24 weeks, once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-003 (1600mg/day)
Description: 24 weeks, once daily oral administration
Study: NCT00701298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02865889

Intervention type: PROCEDURE
Intervention: Laparoscopy in Gynecologic Oncologic Indications

Intervention type: PROCEDURE
Intervention: Conventional surgery (abdominal radical surgery)
Study: NCT01567592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2
Study: NCT01263392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheterization
Description: Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheterization
Description: Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
Study: NCT03784846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training
Description: MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
Study: NCT04006210

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ND0612 Solution for SC infusion
Description: Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ND0612 Solution for SC infusion
Description: Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ND0612 Solution for SC infusion
Description: Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SC infusion
Description: Placebo solution administered SC via infusion pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Oral IR-LD/CD
Description: Encapsulated Placebo for LD/CD 100mg/25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oral IR-LD/CD
Description: Encapsulated Placebo for LD/CD 100mg/25mg
Study: NCT02614040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study: NCT03054350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose
Study: NCT02470143

Intervention type: BEHAVIORAL
Intervention: Bike application arm
Description: The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
Study: NCT02116114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
Study: NCT01654159

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Monofocal IOL
Description: Monofocal Intraocular lens will be implanted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Description: Multifocal IOL will be implanted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toric IOL
Description: Toric IOLS will be implanted
Study: NCT02419131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Headache Therapy
Description: A standard, manualized behavioral intervention for primary headache disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A gold-standard treatment for PTSD, called Cognitive Processing Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual, receiving standard care for PTHA
Study: NCT03060512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Movantik
Description: Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Movantik
Description: Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.
Study: NCT02612701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (nicotine free e-liquid)
Description: Subjects will smoke nicotine free e-liquid with an e-cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (low nicotine e-liquid)
Description: Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (high nicotine e-liquid)
Description: Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
Study: NCT03264105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional resin-based flowable composite
Description: retention rate evaluation of conventional resin-based flowable composite
Study: NCT01488539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAIR/NT treatment
Description: STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.